Resverlogix Announces Presentations at Leading Scientific Conferences - Seite 2
AHA Scientific Sessions, November 13-17, 2020
-
Oral Presentation: BET Protein Inhibitor Apabetalone Suppresses Inflammatory Hyperactivation of Monocytes from Patients with Cardiovascular Disease and Type 2
Diabetes
º Presentation will discuss the important role of macrophage hyperactivation in driving CVD in diabetic patients and demonstrate apabetalone’s reduction of maladaptive gene expression in these cells -
Poster Presentation: Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate
SARS-CoV-2 Viral Entry
º New data will be presented showing apabetalone treatment reduces expression of the angiotensin converting enzyme 2 (ACE2) receptor that is essential for SARS-CoV-2 viral entry, in human cell lines -
Poster Presentation: Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in
Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial
º A new post-hoc analysis of BETonMACE will be presented examining the risk of major adverse cardiovascular events (MACE) events to enrolled patients according to their concomitant insulin treatment
Note: OnDemand sessions will be available for viewing on the AHA Scientific Session’s virtual platform HERE on November 13, 2020 at 9:00 am CDT and will be available on the virtual platform through to November 17, 2020.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.
Lesen Sie auch
BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.